(Overview) Microfluidics for the Characterization of Tumor-specific Extracellular Vesicles

Shannon Stott, PhD
Massachusetts General Hospital

Extracellular vesicles have not seen widespread clinical testing due to limitations in isolation technologies that suffer from low throughput or lack of tumor-specificity. To address this, we have developed a microfluidic platform, the EVHB-Chip, for tumor-specific recovery of EVs using immunoaffinity capture. Through this blood-on-a-chip assay, we aim to gain a better understanding of when these important tumor derived vesicles are released and how we can exploit their molecular content to better guide patient treatment.

This is a brief overview of her talk that occurred during the 2018 Chabner Colloquium.

These lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer.

About The Chabner Colloquium:
Chaired by: Bruce A. Chabner, MD
Massachusetts General Hospital Cancer Center, Harvard Medical School.

This annual Colloquium is held in collaboration with The Massachusetts General Hospital Cancer Center and designed to focus on topics that bring cancer biology to clinical application:
- New targets and targeted agents
- Strategies for profiling and selection of patients for targeted drug trials
- Biomarkers and animal models to guide clinical development